Departments of Medicine and Microbiology and Immunology, Columbia Center for Translational Immunology, Columbia University, New York, NY, United States.
Int Rev Cell Mol Biol. 2019;342:149-173. doi: 10.1016/bs.ircmb.2018.08.001. Epub 2018 Oct 11.
Cancer immunotherapy is based on the ability of the immune system to recognize tumors as foreign tissue. The idea of cancer immunosurveillance was first conceived over a century ago but remained controversial through much of the 20th century. In the past few decades, however, the field has progressed rapidly, and the concept of tumor immunosurveillance is now well established. With this chapter, we provide a historical background of immunosurveillance, the concept of immunoediting, and the role of different T-cell subsets in the tumor microenvironment. We also discuss the relationship between immune checkpoints, tumor antigens, T cell receptor repertoire, and immunosurveillance. Finally, we comment on the future of immunotherapy as it relates to T cell immunosurveillance.
癌症免疫疗法基于免疫系统识别肿瘤为外来组织的能力。癌症免疫监视的概念早在一个多世纪前就提出了，但在 20 世纪的大部分时间里一直存在争议。然而，在过去的几十年里，该领域发展迅速，肿瘤免疫监视的概念现在已经得到很好的确立。通过本章，我们提供了免疫监视的历史背景、免疫编辑的概念以及不同 T 细胞亚群在肿瘤微环境中的作用。我们还讨论了免疫检查点、肿瘤抗原、T 细胞受体库与免疫监视之间的关系。最后，我们就免疫疗法与 T 细胞免疫监视的关系，对其未来发展进行了评论。
